VC  Early Stage Partners

     Office Locations:

1801 East Ninth Street, Suite 1700
Cleveland, OH 44114
Phone: 216-781-4600
Fax: 216-781-0158



  • Early



  • Energy & Clean Tech
  • Information Technology
  • Life Sciences & Healthcare



    Formed in 2001, Early Stage Partners (ESP) invests in information technology, healthcare technologies, advanced manufacturing, and industrial technologies. Managing $100 million in capital, ESP invests primarily in Ohio, Michigan, and the Midwest, though it will consider opportunities in other regions. The firm began raising capital in 2001 and raised $44 million for ESP Fund I, which is now fully deployed. ESP Fund II, with $55 million in commitments, is now actively investing. In addition, a third fund, ESP Fund III, is currently being raised. Early Stage Partners experienced a banner year in 2014, when portfolio companies TOA Technologies, Simbionix and Reverse Medical were sold to strategic investors for a combined value approaching $750 million. TOA Technologies, sold to Oracle, remains the largest ever exit for an Ohio-based software company.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Charles C. MacMillan Chief Financial Officer
    James M. Petras Managing General Partner
    Jonathan P. Murray Managing Director
    Lynn-Ann Gries Lead on Investment for Fund III
    Mike Bunker Managing Director


    Portfolio companies include:

        web link

      Juventas Therapeutics
        web link

        web link


    Recent News: